CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

The CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06073574

Enrollment

160

Registered

2023-10-10

Start date

2021-03-31

Completion date

2026-03-13

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Keywords

TTR, Amyloidosis, Cardiomyopathy

Brief summary

The main purpose of this study is to measure the amyloid burden, defined as extracellular volume (ECV) assessed by Magnetic Resonance Imaging (MRI) over time in a subset of up to 150 participants enrolled in ION-682884-CS2 (NCT04136171).

Detailed description

This pilot study will determine the efficacy of ION-682284 in reducing the amyloid deposit on the heart tissue compared to placebo.

Interventions

DIAGNOSTIC_TESTCardiac MRI

MRI Scans as specified in the corresponding arm group.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

To participate in the ION-682884-CS2MRI sub-study, participants must meet all inclusion criteria of the study protocol ION-682884-CS2 (NCT04136171).

Exclusion criteria

1. Contraindication or sensitivity to MRI contrast agents 2. Orthopnea of sufficient severity to preclude supine scanning at screening. 3. Weight or body girth exceeds the limits of the cardiac MRI machine specifications. 4. Contraindication to cardiac MRI scanning, as assessed by local MRI safety questionnaire/checklist.

Design outcomes

Primary

Measure	Time frame
Change in the Percent of ECV in Participants Receiving ION-682884 vs. Placebo According to ION-682884-CS2 Treatment Groups	From Baseline up to Week 140

Countries

Italy, Spain, United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 15, 2026